[Federal Register Volume 62, Number 76 (Monday, April 21, 1997)] [Notices] [Page 19314] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 97-10201] ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Recombinant F1-V Plague Vaccine AGENCY: U.S. Army Medical Research and Materiel Command, DOD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: In accordance with 38 CFR 404.6, announcement is made of the availability of U.S. Patent Application SN 08/699,716 entitled ``Recombinant F1-V Plague Vaccine,'' filed December 18, 1996. This patent has been assigned to the United States Government as represented by the Secretary of the Army. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, Command Judge Advocate, ATTN: MCMR-JA, 504 Scott Street, Fort Detrick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney, 301-619-7807, Fax 301-619-5034. SUPPLEMENTARY INFORMATION: A recombinant plague vaccine (F1-V) based on a fusion protein composed of the entire capsule protein (F1) and V protein of Yersinia pestis has been developed. Initial preclinical studies in mice have shown this fusion protein when combined with an adjuvant to be efficicacious against fully virulent wild-type and F-1 strains of Yersinia pestis. The vaccine has been tested against both subcutaneous and aerosol challenges, which should mimic the bubonic and pneumonic form of plague. This F1-V vaccine has been shown to be superior to the licensed, whole cell, Plague Vaccine USP in a mouse model. It also offers the advantage of being a defined product which may be less reactogenic than the poorly defined whole cell vaccine. The use of fusion protein offfers advantages of producing and purifying a single protein, instead of two separate components, which may result in lower manufacturing costs. Gregory D. Showalter, Army Federal Register Liaison Officer. [FR Doc. 97-10201 Filed 4-18-97; 8:45 am] BILLING CODE 3710-08-M